[go: up one dir, main page]

UY28650A1 - Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta - Google Patents

Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta

Info

Publication number
UY28650A1
UY28650A1 UY28650A UY28650A UY28650A1 UY 28650 A1 UY28650 A1 UY 28650A1 UY 28650 A UY28650 A UY 28650A UY 28650 A UY28650 A UY 28650A UY 28650 A1 UY28650 A1 UY 28650A1
Authority
UY
Uruguay
Prior art keywords
conduct
memantine
prevention
treatment
suicide
Prior art date
Application number
UY28650A
Other languages
English (en)
Inventor
Charles Flicker
Heikki Hakkarainen
Scott Mcdonald
Original Assignee
Forest Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories filed Critical Forest Laboratories
Publication of UY28650A1 publication Critical patent/UY28650A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con el tratamiento del trastorno depresivo mayor (TDM), así como con la prevención de la conducta suicida asociada con el mismo, mediante la utilización de memantina, un antagonista no competitivo del receptor de NMDA.
UY28650A 2003-12-05 2004-12-02 Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta UY28650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52726803P 2003-12-05 2003-12-05

Publications (1)

Publication Number Publication Date
UY28650A1 true UY28650A1 (es) 2005-02-28

Family

ID=34676726

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28650A UY28650A1 (es) 2003-12-05 2004-12-02 Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta

Country Status (13)

Country Link
US (1) US20050282911A1 (es)
EP (1) EP1694316A1 (es)
JP (1) JP2007513169A (es)
KR (1) KR20070051770A (es)
CN (1) CN1889938A (es)
AR (1) AR046868A1 (es)
AU (1) AU2004296790A1 (es)
CA (1) CA2546496A1 (es)
EA (1) EA200601103A1 (es)
MX (1) MXPA06006397A (es)
TW (1) TW200519067A (es)
UY (1) UY28650A1 (es)
WO (1) WO2005055996A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
ATE506945T1 (de) * 2004-09-20 2011-05-15 Sinai School Medicine Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
JP4753683B2 (ja) * 2005-10-14 2011-08-24 オルテック インコーポレイテッド 細胞機能を変化させるための方法および組成物
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US7621871B2 (en) * 2006-06-16 2009-11-24 Archinoetics, Llc Systems and methods for monitoring and evaluating individual performance
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP3659604A1 (en) * 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
AU2016274988A1 (en) 2015-06-12 2017-12-21 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
WO2018209341A1 (en) * 2017-05-12 2018-11-15 Indiana University Research And Technology Corporation Precision medicine for treating and preventing suicidality
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN113395962A (zh) * 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
EP4464377A3 (en) * 2019-02-22 2025-02-26 GH Research Ireland Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
DE19644998C1 (de) * 1996-10-30 1998-06-10 Hanns Prof Dr Ludwig Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
EA002254B1 (ru) * 1997-06-30 2002-02-28 Мерц + Ко. Гмбх Унд Ко. 1-аминоалкилциклогексановые антагонисты рецепторов nmda
BR0116001A (pt) * 2000-12-07 2004-07-06 Neuromolecular Inc Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20050065219A1 (en) * 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions

Also Published As

Publication number Publication date
MXPA06006397A (es) 2006-08-23
US20050282911A1 (en) 2005-12-22
KR20070051770A (ko) 2007-05-18
WO2005055996A1 (en) 2005-06-23
EP1694316A1 (en) 2006-08-30
CN1889938A (zh) 2007-01-03
AU2004296790A1 (en) 2005-06-23
JP2007513169A (ja) 2007-05-24
CA2546496A1 (en) 2005-06-23
AR046868A1 (es) 2005-12-28
TW200519067A (en) 2005-06-16
EA200601103A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
UY28650A1 (es) Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
PA8576901A1 (es) Moduladores del receptor de glucocorticoides
ECSP10010409A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
PH12022550510A1 (en) Conjugated hepcidin mimetics
ECSP088817A (es) Métodos para usar el receptor gpr119 en la identificación de compuestos útiles para aumentar la masa ósea en un individuo
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
MY172151A (en) Certain chemical entities, compositions and methods
BR122019021238B8 (pt) uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
NO20073293L (no) Toll-liknende reseptor-3-antagonister, fremgangsmater og anvendelser
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
ATE469895T1 (de) Cgrp-rezeptorantagonisten
GB2453058A (en) Kinase antagonists
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
CL2011000976A1 (es) Compuestos derivados de isonicotinamida y carboxamida, antagonistas de los receptores de orexina; composicion farmaceutica que los comprende; y su uso para la prevencion de un trastorno del sueno.
MX394875B (es) Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
CL2009000660A1 (es) Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor.
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150609